COMPOUND FOR INHIBITING BRUTON'S TYROSINE KINASE, AND PHARMACEUTICAL USE THEREOF

WIPO Patent Application WO/2022/149856

A1

The present invention provides a compound, having a specific chemical structure, having a Bruton's tyrosine kinase (BTK)-inhibiting activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition comprising the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing BTK-related diseases, of the compound according to the present invention, a salt thereof, and a composition comprising the compound or the salt. The present invention also provides a method for treating or preventing BTK-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition comprising the compound or the salt to a subject in need of treatment.

KIM SUNG-EUN (KR)
LEE SUN-HO (KR)
LEE YONG-HYUB (KR)
KONG YUNJEONG (KR)
BAEK MINSEO (KR)
KIM MIN JUNG (KR)

PCT/KR2022/000173

July 14, 2022

January 05, 2022

Click for automatic bibliography generation  

ONCOBIX CO LTD (KR)

C07D491/048; A61K31/519; A61P25/00; A61P29/00; A61P35/00; A61P37/02; C07D491/107

WO2019046163A1	2019-03-07
WO2016130920A2	2016-08-18

KR20180088318A	2018-08-03
KR20180137057A	2018-12-27

CZARNA ANNA, WANG JINHUA, ZELENCOVA DIANA, LIU YAO, DENG XIANMING, CHOI HWAN GEUN, ZHANG TINGHU, ZHOU WENJUN, CHANG JAE WON, KILDA: "Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 17, 13 September 2018 (2018-09-13), US , pages 7560 - 7572, XP055843576, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b01847

PHIL & ONZI INT'L PATENT & LAW FIRM (KR)

View/Download PDF      PDF Help

Previous Patent: HETEROARYL-ETHYNYL DERIVATIVE COMPOUND AND USE THEREOF

Next Patent: ELECTRONIC DEVICE CAPABLE OF REDUCING DAMAGE TO GLASS